A naukri.com initiative
Bioengineer
20h
44
Image Credit: Bioengineer
Organ Preservation in Lung Cancer: Extended Sleeve Lobectomy Following Neoadjuvant Immunochemotherapy Emerges as Optimal Strategy for Centrally Located NSCLC
- A retrospective study in the April 2025 Annals of Thoracic Surgery highlights extended sleeve lobectomy (ESL) after neoadjuvant immunochemotherapy as a safe and effective option for centrally located NSCLC.
- ESL offers a lung-preserving alternative to pneumonectomy, with high rates of complete tumor resection (R0) and comparable morbidity to standard sleeve lobectomy (SSL).
- Postoperative complications were contained at 18.1%, showing ESL's safety post-immunochemotherapy and challenging assumptions about increased risks.
- Kaplan-Meier analyses revealed no significant difference in event-free survival between ESL and SSL, with ESL even showing improved outcomes over pneumonectomy.
- ESL post-neoadjuvant immunochemotherapy preserves lung function, reduces morbidity, and may enhance oncological results, marking a critical advancement in thoracic surgery.
- The study emphasizes multidisciplinary collaboration, personalized treatments, and the transformative impact of immunotherapy on surgical options for NSCLC.
- ESL requires expert surgical skills, thorough preoperative planning, and vigilant perioperative management to optimize outcomes for centrally located NSCLC patients.
- The research advocates for broader adoption of ESL, potentially influencing guidelines and training in thoracic surgery, ultimately improving patient survival and quality of life.
- This evidence underscores the synergy between neoadjuvant immunochemotherapy and ESL, reshaping standards of care and enhancing lung cancer treatment paradigms.
- The study establishes ESL as a crucial surgical alternative, offering hope for improved outcomes and patient-centered care in the management of centrally located NSCLC.
- Web Story Eligibility: True
Read Full Article
2 Likes
For uninterrupted reading, download the app